K
Kuen Haur Lee
Researcher at Taipei Medical University
Publications - 44
Citations - 1088
Kuen Haur Lee is an academic researcher from Taipei Medical University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 14, co-authored 41 publications receiving 738 citations. Previous affiliations of Kuen Haur Lee include Taipei Medical University Hospital.
Papers
More filters
Journal ArticleDOI
MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway
I-Shan Hsieh,Kung Chao Chang,Yao Tsung Tsai,Jhen-Yu Ke,Pei Jung Lu,Kuen Haur Lee,Shauh-Der Yeh,Tse-Ming Hong,Yuh Ling Chen +8 more
TL;DR: Results support that miR-320 is a key negative regulator in prostate TICs, and suggest developing mi R-320 as a novel therapeutic agent may offer benefits for PCa treatment.
Journal ArticleDOI
MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1.
Kuen Haur Lee,Forn Chia Lin,Tai I. Hsu,Jen Tai Lin,Jing Hong Guo,Chen Hsun Tsai,Yu Cheng Lee,Yu Chieh Lee,Chi Long Chen,Michael Hsiao,Pei Jung Lu +10 more
TL;DR: It is shown that the mRNA expression levels of Pin1 were not correlated with Pin1 protein levels in prostate cell lines which indicated that Pin1 may be regulated at the post-transcriptional level, and potential effects of miR-296-5p on the prognosis and clinical application to prostate cancer therapy are implicate.
Journal ArticleDOI
Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance
Chia-Hung Liu,Wan-Chun Tang,Peik Sia,Chi-Chen Huang,Pei Ming Yang,Ming-Heng Wu,I-Lu Lai,Kuen Haur Lee +7 more
TL;DR: Berberine should be developed as a pharmacological agent for use in combination with other anticancer drug for treating metastatic prostate cancer.
Journal ArticleDOI
Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer
Yen-Hao Su,Wan-Chun Tang,Ya-Wen Cheng,Peik Sia,Chi-Chen Huang,Yi-Chao Lee,Hsin-Yi Jiang,Ming-Heng Wu,I-Lu Lai,Jun-Wei Lee,Kuen Haur Lee +10 more
TL;DR: Results indicate that combination of NVP-AUY922 and BBR therapy can inhibit multiple oncogenic signaling pathways of CRC.
Journal ArticleDOI
Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer
Tzu-Jen Kao,Chung-Che Wu,Chung-Che Wu,Nam Nhut Phan,Yen-Hsi Liu,Hoang Dang Khoa Ta,Gangga Anuraga,Yung-Fu Wu,Kuen Haur Lee,Jian-Ying Chuang,Jian-Ying Chuang,Chih-Yang Wang +11 more
TL;DR: Investigation of potential roles of six PSMC family members in breast cancer at the messenger RNA level and their correlations with patient survival discovered that high levels of PSMC1, PSMC3, PS MC4,PSMC5, and PSMC6 transcripts were positively correlated with poor survival, which likely shows their importance in Breast cancer development.